Navigation Links
1st Case Report of Using Single-Site Cannulation ECMO to Treat SynCardia Total Artificial Heart Patient Published in Journal of Cardiothoracic Surgery
Date:8/21/2013

TUCSON, Ariz., Aug. 21, 2013 /PRNewswire/ -- SynCardia Systems, Inc. (www.syncardia.com), manufacturer of the world's first and only FDA, Health Canada and CE (Europe) approved Total Artificial Heart, announced today that doctors at EJK Duisburg in Germany have published the first case report detailing use of single-site cannulation with extracorporeal membrane oxygenation (ECMO) to successfully treat adult respiratory distress syndrome in a patient implanted with the SynCardia temporary Total Artificial Heart. The case report was published in the August issue of the Journal of Cardiothoracic Surgery.

(Photo:  http://photos.prnewswire.com/prnh/20130821/LA67168)

Before the Total Artificial Heart implant, the 55-year-old patient was supported by veno-arterial ECMO due to refractory cardiogenic shock and severe respiratory failure. Once the Total Artificial Heart was implanted, the patient was weaned from extracorporeal circulation. However, due to pre-existing respiratory failure, doctors decided to implement veno-venous ECMO using a single-site bicaval dual-lumen catheter placed in the right internal jugular vein instead of conventional dual-site cannulation.

"In this context single-site veno-venous cannulation proved to have numerous advantages: it is simple to perform, it minimizes the risk of cannula dislodgement during patient care, reduces the risk of catheter related infections and finally allows early sternum closure," according to the report written by Dr. Sotirios Spiliopoulos, surgeons Dr. Guenes Dogan and Dr. Dilek Guersoy, intensivist Dr. Maria Rosario Serrano and Prof. Reiner Koerfer and Prof. Gero Tenderich, the implanting surgeon.

"Single-site venous cannulation could be a reasonable alternative to conventional cannulation for ECMO support in SynCardia Total Artificial Heart patients with an adult respiratory distress syndrome," the report concluded.

"This is an excellent case report," said Dr. Francisco Arabia, who has implanted more than 100 SynCardia Total Artificial Hearts. Arabia co-authored one of the articles cited in the August case report. That article dealt with parallel ECMO and artificial heart applications. He has proctored the first implant at more than a dozen hospitals qualifying these centers of excellence to become SynCardia Certified Centers.

About the SynCardia temporary Total Artificial Heart

SynCardia Systems, Inc. (Tucson, AZ) is the privately-held manufacturer of the world's first and only FDA, Health Canada and CE approved Total Artificial Heart. Originally used as a permanent replacement heart, the SynCardia Total Artificial Heart is currently approved as a bridge to transplant for people suffering from end-stage heart failure affecting both sides of the heart (biventricular failure). There have been more than 1,200 implants of the Total Artificial Heart, accounting for more than 335 patient years of life on the device.

Similar to a heart transplant, the SynCardia Total Artificial Heart replaces both failing heart ventricles and the four heart valves. Unlike a donor heart, the Total Artificial Heart is immediately available at SynCardia Certified Centers. It is the only device that eliminates the symptoms and source of end-stage biventricular failure.

The Total Artificial Heart provides immediate, safe blood flow of up to 9.5 liters per minute through each ventricle. This high volume of blood flow helps speed the recovery of vital organs, helping make the patient a better transplant candidate.

Forbes Ranks SynCardia #69 Among "America's Most Promising Companies"

In its February 2013 issue, Forbes selected SynCardia as one of "America's Most Promising Companies" for the second consecutive year. On the list of 100 privately held, high-growth companies with bright futures, SynCardia was selected #69, moving up eight spots from its #77 ranking last year. See the full list of SynCardia Awards & Recognition here.

For up-to-date information, please visit: http://www.syncardia.com
Like SynCardia on Facebook - http://www.facebook.com/pages/SynCardia-Systems-Inc/191245900926019
Follow SynCardia on Twitter – http://twitter.com/SynCardia


'/>"/>
SOURCE SynCardia Systems, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Cell Therapeutics, Inc. (CTI) to Report First Quarter Financial Results on April 20
2. Report Presents a Framework for Successful New Oncology Product Launches in the Pharmaceutical Sector
3. WuXi PharmaTech Files 2011 Annual Report on Form 20-F
4. Qmed, the Leading Global MedTech Industry Resource, Partners with Clarimed, to Provide the Medical Manufacturing and Healthcare Industry with FDA Reports on Adverse Events
5. Sigma-Aldrich (NASDAQ: SIAL) Reports Q1 2012 Diluted EPS of $0.96, With Diluted Adjusted EPS of $0.99. Sales Increase 5% for Q1 2012. Full Year 2012 Diluted Adjusted EPS Outlook of $3.90 to $4.05 Reaffirmed.
6. Kelyniam Global Inc. Reports Record Cranial Implant Revenues in the 1st Quarter of 2012
7. Varian Medical Systems Reports Results for Second Quarter of Fiscal Year 2012
8. Mylan Reports Q1 2012 Adjusted Diluted EPS of $0.52, an 18% Increase Over Prior Year Quarter
9. CryoLife Reports Record Quarterly Revenues in First Quarter of 2012
10. Chindex International, Inc. to Report First Quarter 2012 Financial Results
11. Pharma IQs Solubility Report
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Systemic Lupus Erythematosus ...  report to their offering.       ... The latest research Europe Systemic Lupus Erythematosus ... provides comprehensive insights into Systemic Lupus Erythematosus ...
(Date:5/4/2016)... COUNTY, Calif. , May 4, 2016  It,s time for an upgrade. There ... shown on a brilliant 3.5 inch LCD, the illustrious DVMAXX HD  offers unparalleled ... brands as well as a world class manufacturer of innovative technology.  Photo ... ... ...
(Date:5/4/2016)... , May 4, 2016 ... Jerusalem announced today that it had signed an ... Inc. , developer of novel protein degradation and immunomodulatory ... and commercialization of drug candidates representing first-in-class therapy for ... were not disclosed. The novel technology was ...
Breaking Medicine Technology:
(Date:5/6/2016)... ... May 06, 2016 , ... ... TX has announced the latest beneficiary of their ongoing community enrichment program. The ... childhood leukemia. Young Mason McGaughey faces many more months of treatments, leaving his ...
(Date:5/6/2016)... ... 06, 2016 , ... The joy associated with Mother’s Day is mixed with worry and fear ... units (NICUs) across the country. For the first time ever, the March of Dimes ... who spend their Mother’s Day beside a crib surrounded by lifesaving equipment or peering through ...
(Date:5/6/2016)... ... May 06, 2016 , ... A wide variety of national pet product manufacturers, companies and brands ... Media Showcase Wednesday, May 18 from noon to 8 p.m. at New York City’s Roger ... new and established home, garden, outdoor and safety pet products in today’s marketplace. ...
(Date:5/6/2016)... ... May 06, 2016 , ... Fat-Freezing, which is what ... body, is the most popular among body sculpting options, according to a new ... cosmetic surgeon Dr. Richard Buckley, medical director of MilfordMD Cosmetic Dermatology Surgery & ...
(Date:5/6/2016)... ... May 06, 2016 , ... From May 4 to 6, ... members the unique opportunity to learn more about Signia’s technology and the successful business ... “It is our priority to see practices succeed in this highly competitive industry,” said ...
Breaking Medicine News(10 mins):